Key facts
- This page summarizes John E. Bishop's Form 4 filing for Forma Therapeutics Holdings, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 15 Jun 2021, 16:15.
John E. Bishop - 14 Jun 2021 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.
- Reporting relationship
- Chief Technology Officer
- Issuer ticker
- N/A
- Reported as of
- 14 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 15 Jun 2021, 16:15:00 UTC
- Next SEC filing
- 02 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeannette Potts, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
John E. Bishop filed Form 4 for Forma Therapeutics Holdings, Inc. on 15 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FMTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +22,000
- Change %
- Price
- $0.000000
- Shares after
- 22,000
- Date
- 14 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FMTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +67,000
- Change %
- Price
- $0.000000
- Shares after
- 67,000
- Date
- 14 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 67,000
- Exercise price
- $24.26
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
Footnote F2
25% of the shares subject to the stock option shall vest on June 14, 2022, and the remainder of the shares shall vest in equal monthly installments for a period of 36 months thereafter, subject to continued service with the Issuer.